Assertio Therapeutics Inc (ASRT) - Net Assets
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has net assets worth $93.95 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($266.97 Million) and total liabilities ($173.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Assertio Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $93.95 Million |
| % of Total Assets | 35.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | -8.26% |
| 10-Year Change | -62.54% |
| Growth Volatility | 140.36 |
Assertio Therapeutics Inc - Net Assets Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore ASRT total assets for the complete picture of this company's asset base.
Annual Net Assets for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual net assets of Assertio Therapeutics Inc from 1996 to 2025. For live valuation and market cap data, see ASRT market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $93.95 Million | -22.41% |
| 2024-12-31 | $121.08 Million | -12.26% |
| 2023-12-31 | $138.00 Million | -38.86% |
| 2022-12-31 | $225.72 Million | +120.40% |
| 2021-12-31 | $102.41 Million | +84.48% |
| 2020-12-31 | $55.51 Million | -4.22% |
| 2019-12-31 | $57.96 Million | -73.70% |
| 2018-12-31 | $220.34 Million | +29.99% |
| 2017-12-31 | $169.51 Million | -32.41% |
| 2016-12-31 | $250.79 Million | -20.40% |
| 2015-12-31 | $315.06 Million | -13.55% |
| 2014-12-31 | $364.45 Million | +165.21% |
| 2013-12-31 | $137.42 Million | +63.72% |
| 2012-12-31 | $83.94 Million | -20.75% |
| 2011-12-31 | $105.92 Million | +358.40% |
| 2010-12-31 | $23.11 Million | +46.93% |
| 2009-12-31 | $15.73 Million | -52.57% |
| 2008-12-31 | $33.15 Million | -27.17% |
| 2007-12-31 | $45.52 Million | +266.81% |
| 2006-12-31 | $-27.29 Million | -503.62% |
| 2005-12-31 | $6.76 Million | -19.54% |
| 2004-12-31 | $8.40 Million | -75.70% |
| 2003-12-31 | $34.58 Million | +639.08% |
| 2002-12-31 | $-6.41 Million | -334.19% |
| 2001-12-31 | $-1.48 Million | -132.21% |
| 2000-12-31 | $4.59 Million | -50.25% |
| 1999-12-31 | $9.22 Million | +0.20% |
| 1998-12-31 | $9.20 Million | +124.39% |
| 1997-12-31 | $4.10 Million | +1125.00% |
| 1996-12-31 | $-400.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Assertio Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 70239900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $797.45 Million | 848.78% |
| Total Equity | $93.95 Million | 100.00% |
Assertio Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Assertio Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mitrabara Adiperdana PT
JK:MBAP
|
$118.66 Million |
|
Distribuidora de Gas Cuyana SA
BA:DGCU2
|
$118.67 Million |
|
Eastern Water Resources Development and Management Public Company Limited
F:7ES1
|
$118.69 Million |
|
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
|
$118.88 Million |
|
Shanghai Diesel Engine Co Ltd B
SHG:900920
|
$118.61 Million |
|
SYN prop e tech S.A.
SA:SYNE3
|
$118.61 Million |
|
Finder Energy Holdings Ltd
AU:FDR
|
$118.61 Million |
|
RTX A/S
CO:RTX
|
$118.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Assertio Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 121,081,000 to 93,952,000, a change of -27,129,000 (-22.4%).
- Net loss of 29,505,000 reduced equity.
- Share repurchases of 189,000 reduced equity.
- Other factors increased equity by 2,565,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.50 Million | -31.4% |
| Share Repurchases | $189.00K | -0.2% |
| Other Changes | $2.56 Million | +2.73% |
| Total Change | $- | -22.41% |
Book Value vs Market Value Analysis
This analysis compares Assertio Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $-5.76 | $18.47 | x |
| 1997-12-31 | $55.35 | $18.47 | x |
| 1998-12-31 | $87.37 | $18.47 | x |
| 1999-12-31 | $85.43 | $18.47 | x |
| 2000-12-31 | $37.54 | $18.47 | x |
| 2001-12-31 | $-8.67 | $18.47 | x |
| 2002-12-31 | $-26.28 | $18.47 | x |
| 2003-12-31 | $84.82 | $18.47 | x |
| 2004-12-31 | $14.56 | $18.47 | x |
| 2005-12-31 | $10.19 | $18.47 | x |
| 2006-12-31 | $-39.44 | $18.47 | x |
| 2007-12-31 | $58.92 | $18.47 | x |
| 2008-12-31 | $40.78 | $18.47 | x |
| 2009-12-31 | $18.31 | $18.47 | x |
| 2010-12-31 | $25.98 | $18.47 | x |
| 2011-12-31 | $113.30 | $18.47 | x |
| 2012-12-31 | $90.10 | $18.47 | x |
| 2013-12-31 | $143.28 | $18.47 | x |
| 2014-12-31 | $21.99 | $18.47 | x |
| 2015-12-31 | $20.96 | $18.47 | x |
| 2016-12-31 | $16.37 | $18.47 | x |
| 2017-12-31 | $162.20 | $18.47 | x |
| 2018-12-31 | $205.89 | $18.47 | x |
| 2019-12-31 | $49.18 | $18.47 | x |
| 2020-12-31 | $31.77 | $18.47 | x |
| 2021-12-31 | $35.59 | $18.47 | x |
| 2022-12-31 | $61.93 | $18.47 | x |
| 2023-12-31 | $29.14 | $18.47 | x |
| 2024-12-31 | $19.06 | $18.47 | x |
| 2025-12-31 | $14.67 | $18.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Assertio Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.85%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.84x
- Recent ROE (-31.40%) is above the historical average (-65.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 0.00% | -166.67% | 1.00x | 0.00x | $-460.00K |
| 1997 | -29.27% | -200.00% | 0.13x | 1.12x | $-1.61 Million |
| 1998 | -30.43% | -350.00% | 0.08x | 1.12x | $-3.72 Million |
| 1999 | -186.68% | -14921.74% | 0.01x | 2.43x | $-18.13 Million |
| 2000 | -211.57% | -546.27% | 0.20x | 1.90x | $-10.16 Million |
| 2001 | 0.00% | -479.13% | 0.42x | 0.00x | $-17.45 Million |
| 2002 | 0.00% | -812.35% | 0.07x | 0.00x | $-12.85 Million |
| 2003 | -86.81% | -3056.56% | 0.02x | 1.38x | $-33.47 Million |
| 2004 | -319.80% | -13266.41% | 0.01x | 2.72x | $-27.71 Million |
| 2005 | -361.89% | -555.40% | 0.07x | 9.82x | $-25.14 Million |
| 2006 | 0.00% | -415.23% | 0.18x | 0.00x | $-36.93 Million |
| 2007 | 108.13% | 75.05% | 0.81x | 1.77x | $44.67 Million |
| 2008 | -46.16% | -43.92% | 0.37x | 2.87x | $-18.62 Million |
| 2009 | -139.95% | -38.12% | 0.63x | 5.82x | $-23.58 Million |
| 2010 | 16.86% | 4.82% | 0.93x | 3.77x | $1.59 Million |
| 2011 | 66.77% | 53.19% | 0.81x | 1.55x | $60.13 Million |
| 2012 | -35.48% | -32.79% | 0.64x | 1.69x | $-38.17 Million |
| 2013 | 31.52% | 32.27% | 0.26x | 3.70x | $29.57 Million |
| 2014 | 36.15% | 33.75% | 0.55x | 1.95x | $95.32 Million |
| 2015 | -24.04% | -22.10% | 0.25x | 4.33x | $-107.24 Million |
| 2016 | -35.38% | -19.46% | 0.37x | 4.89x | $-113.80 Million |
| 2017 | -60.47% | -26.92% | 0.37x | 6.13x | $-119.45 Million |
| 2018 | 16.75% | 11.84% | 0.33x | 4.23x | $14.87 Million |
| 2019 | -374.76% | -94.63% | 0.44x | 9.10x | $-223.00 Million |
| 2020 | -50.70% | -26.04% | 0.36x | 5.46x | $-33.70 Million |
| 2021 | -1.25% | -1.15% | 0.34x | 3.19x | $-11.52 Million |
| 2022 | 48.57% | 70.17% | 0.38x | 1.83x | $87.05 Million |
| 2023 | -240.53% | -218.28% | 0.53x | 2.08x | $-345.74 Million |
| 2024 | -17.82% | -17.27% | 0.44x | 2.35x | $-33.69 Million |
| 2025 | -31.40% | -24.85% | 0.44x | 2.84x | $-38.90 Million |
Industry Comparison
This section compares Assertio Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Assertio Therapeutics Inc (ASRT) | $93.95 Million | 0.00% | 1.84x | $118.66 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more